Exxon Mobil Corp
Change company Symbol lookup
Select an option...
XOM Exxon Mobil Corp
NEWR New Relic Inc
T AT&T Inc
AICAF Air China Ltd
MMM 3M Co
JNJ Johnson & Johnson
TIP iShares TIPS Bond ETF
OCUL Ocular Therapeutix Inc
NLY Annaly Capital Management Inc
APM Aptorum Group Ltd
Go

Energy : Oil, Gas & Consumable Fuels | Large Cap Value
Company profile

Exxon Mobil Corporation is engaged in energy business. The Company is engaged in the exploration, production, transportation and sale of crude oil and natural gas, and the manufacture, transportation and sale of petroleum products. The Company also manufactures and markets commodity petrochemicals, including olefins, aromatics, polyethylene and polypropylene plastics, and a range of specialty products. The Company's segments include Upstream, Downstream, Chemical, and Corporate and Financing. The Upstream segment operates to explore for and produce crude oil and natural gas. The Downstream operates to manufacture and sell petroleum products. The Chemical segment operates to manufacture and sell petrochemicals. The Company has exploration and development activities in projects located in the United States, Canada/South America, Europe, Africa, Asia and Australia/Oceania.

Postmarket

Last Trade
Delayed
$34.28
0.00 (0.00%)
Bid
--
Ask
--
B/A Size
--

Market Hours

Closing Price
$34.28
Day's Change
-1.03 (-2.92%)
Bid
--
Ask
--
B/A Size
--
Day's High
35.11
Day's Low
33.99
Volume
(Light)
Volume:
20,759,700

10-day average volume:
29,377,504
20,759,700

Gilead CAR-t therapy receives FDA approval

1:31 pm ET July 27, 2020 (MarketWatch)
Print

Gilead Sciences Inc. (GILD) said late Friday that its CAR-T cell therapy had received approval from the Food and Drug Administration as a treatment for adult patients with relapsed or refractory mantle cell lymphoma. Shares of Gilead were up 0.6% in trading on Monday. The list price for Tecartus is $373,000 for a one-time infusion, according to a Gilead spokesperson, who noted by email that 87% of patients who receive a single dose report a response to the therapy. The "approval should also help quell at least in part any concerns that part two of the first wave of COVID-19 cases or the vaccine development race is distracting the FDA from approving important cancer medications," Mizuho Securities analyst Salim Syed wrote in a note to investors on Friday. Gilead's stock has gained 14.1% so far this year, while the S&P 500 has declined 0.4%.

-Jaimy Lee; 415-439-6400; AskNewswires@dowjones.com

(END) Dow Jones Newswires

July 27, 2020 13:31 ET (17:31 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.